Angiotensin-Converting Enzyme Inhibitors (ACEIs), Angiotensin II Receptor Antagonists (ARBs), or Direct Renin Inhibitors (DRI) for Adults With Hypertension
Evidence on Adverse Effects: Angioedema
Angioedema is a potentially salient and serious adverse event, however, it was not reported in the majority of studies, making it impossible to accurately characterize its frequency and timing in this population. In the four studies that did report episodes of angioedema, this adverse event was observed only in patients treated with an ACEI or DRI (only one reported case). The results from these studies were not pooled because in studies that did not report angioedema, it was not clearly valid to infer that there were no events simply because the studies did not report explicitly that an episode of angioedema did not occur. Thus, it was not possible to estimate the frequency of angioedema in this population.
- Sanders GD, Coeytaux R, Dolor RJ, et al. Angiotensin-Converting Enzyme Inhibitors (ACEIs), Angiotensin II Receptor Antagonists (ARBs), and Direct Renin Inhibitors for Treating Essential Hypertension: An Update. Comparative Effectiveness Review No. 34. (Prepared by the Duke Evidence-based Practice Center under Contract No. 290-02-0025.) AHRQ Publication No. 11-EHC063-EF. Rockville, MD: Agency for Healthcare Research and Quality. June 2011. Available at: http://www.effectivehealthcare.ahrq.gov/index.cfm/search-for-guides-reviews-and-reports/?pageaction=displayproduct&productID=696.
Your slide tray is being processed.